Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis
- 1 February 2016
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in European Journal of Gastroenterology & Hepatology
- Vol. 28 (2), 217-221
- https://doi.org/10.1097/meg.0000000000000515
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosisJournal of Crohn's and Colitis, 2012
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative ColitisGastroenterology, 2011
- The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel DiseaseDigestive and Liver Disease, 2011
- Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or InfliximabGastroenterology, 2009
- Long-term outcome after infliximab for refractory ulcerative colitisJournal of Crohn's and Colitis, 2008
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2005
- Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled StudyGastroenterology, 2005
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseThe New England Journal of Medicine, 2003
- Colorectal cancer risk and mortality in patients with ulcerative colitisGastroenterology, 1992